![](https://aionlabs.com/wp-content/uploads/2024/01/denov-ai@3x.png)
Denovai
Dynamic protein design
DenovAI aims to rapidly accelerate drug discovery by developing a novel, AI-based platform that can design high affinity therapeutic antibody and miniprotein binders for protein targets of choice, completely from scratch.
![](https://aionlabs.com/wp-content/uploads/2024/01/promise-bio@3x.png)
Promise Bio
Deep cellular insights
Promise Bio is developing the first platform that performs unbiased, broad-range epiproteomic analysis for precision medicine in complex chronic conditions, including autoimmune diseases. Our cloud-based platform delivers timely, clinically valuable insights to enable treatment personalization and response predictions.
![](https://aionlabs.com/wp-content/uploads/2024/01/ten-aces@3x.png)
tenAces
Molecular glue discovery
TenAces Biosciences aims to improve patients’ lives by developing rationally designed molecular glue therapeutics for enhanced targeted protein degradation. Using a data centric approach and machine learning, TenAces is able to study the various interactions, protein pairs, and multi-dimensional features to predict new molecular glues.
![](https://aionlabs.com/wp-content/uploads/2024/01/combinable@3x_n.png)
Combinable
Tailored antibody optimization
Combinable addresses a key challenge of trial-and-error in pharma development and manufacturing, by developing an in silico solution that optimizes properties concurrently. This approach seeks to identify multiple drug candidates that achieve a balanced profile across diverse characteristics, thus expediting and refining the drug discovery process.
![](https://aionlabs.com/wp-content/uploads/2024/01/omec@3x.png)
Omec
Deep cellular insights
Omec.AI aims to improve the probability of success of drug candidates in clinical trials by analyzing pre-clinical safety and efficacy data. OMEC.AI builds a next-generation computational platform that can identify hidden safety liabilities and lack of efficacy for drug candidates, and suggest experiments to close the identified gaps.
Past Challenges
Call for Applications: Entrepreneur in Residence for New Venture Leveraging AI for Clinical Trial Control Arms
AI/ML Platform for Targeting RNA With Small Molecules challenge
![](https://aionlabs.com/wp-content/uploads/2024/02/Small-Challenge-07@2x.png)
Identification of Active Small Molecules for Drug Discovery challenge
![](https://aionlabs.com/wp-content/uploads/2024/02/challenge_6.png)
AI Powered Discovery to Enable Molecular Glue Therapies challenge
![](https://aionlabs.com/wp-content/uploads/2024/02/challenge_5.png)
Prediction of clinical trial outcome in biomarker stratified cancer patient populations challenge
![](https://aionlabs.com/wp-content/uploads/2024/02/challenge_4_n.png)
Artificial Intelligence for Design and Optimization of Antibodies for Targeted Therapies challenge
![](https://aionlabs.com/wp-content/uploads/2024/02/challenge_3.png)
Artificial Intelligence to Predict Clinical Trial Readiness of Drug Candidates challenge
![](https://aionlabs.com/wp-content/uploads/2024/02/challenge_2_n.png)